Tigecycline (220620-09-7) is a clinically useful antibiotic.1,2 It is a glycylcycline derivative of minocycline that binds to the 30S ribosomal subunit of bacteria blocking the interaction of aminoacyl-tRNA with the ribosome. Tigecycline is active against Gram-positive and -negative bacteria, anaerobic bacteria and drug resistant bacteria such as MRSA, MRSE, and VRE. Tigecycline has also been shown to be selectively toxic to human acute myeloid leukemia cells over normal hematopoietic cells via inhibition of mitochondrial protein translation.3 It has also been found to be effective against other cancers including non-small cell lung cancer4, melanoma5, lymphoma6, and osteosarcoma7.
1) Greer (2006) Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics; Proc. (Bayl. Univ. Med. Cent.) 19 155
2) Peterson (2008) A review of tigecycline – the first glycylcycline; Int. J. Antimicrob. Agents 32 Suppl 4 S215
3) Skrtic et al. (2011) Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia; Cancer Cell 20 674
4) Jia et al. (2016) Tigecyclin targets nonsmall cell lung cancer through inhibition of mitochondrial function; Fundam. Clin. Pharmacol. 30 297
5) Hu et al. (2016) Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner; Oncotarget 7 3171
6) D’Andrea et al. (2016) The mitochondrial translational machinery as a therapeutic target in Myc-driven lymphomas.; Oncotarget 7 72415
7) Chen et al. (2019) Inhibition of mitochondrial translation selectively targets osteosarcoma; Biochem. Biophys. Res. Commun. 515 9